Please wait a minute...
 Home  About the Journal Editorial Board Aims & Scope Peer Review Policy Subscription Contact us
Early Edition  //  Current Issue  //  Open Special Issues  //  Archives  //  Most Read  //  Most Downloaded  //  Most Cited
Aging and disease    2020, Vol. 11 Issue (4) : 874-894     DOI: 10.14336/AD.2020.0520
Review |
Multi-organ Dysfunction in Patients with COVID-19: A Systematic Review and Meta-analysis
Wu Ting1,2, Zuo Zhihong1,3, Kang Shuntong1,3, Jiang Liping3, Luo Xuan4, Xia Zanxian5,6, Liu Jing1, Xiao Xiaojuan1, Ye Mao7, Deng Meichun1,3,6,*
1Department of Biochemistry and Molecular Biology & Hunan Province Key Laboratory of Basic and Applied Hematology, School of Life Sciences, Central South University, Hunan 410013, China.
2Department of Cardiovascular Medicine, The Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, China.
3Xiangya School of Medicine, Central South University, Hunan 410013, China.
4Hunan Yuanpin Cell Biotechnology Co., Ltd, Hunan 410129, China.
5Department of Cell Biology, School of Life Sciences, Central South University, Changsha 410013, China.
6Hunan Key Laboratory of Animal Models for Human Diseases, Hunan Key Laboratory of Medical Genetics & Center for Medical Genetics, School of Life Sciences, Central South University, Changsha 410013, China.
7Molecular Science and Biomedicine Laboratory, State Key Laboratory for Chemo/Biosensing and Chemometrics, College of Biology, College of Chemistry and Chemical Engineering, Collaborative Innovation Center for Molecular Engineering for Theranostics, Hunan University, Changsha, China
Download: PDF(3152 KB)   HTML
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks    

This study aimed to provide systematic evidence for the association between multiorgan dysfunction and COVID-19 development. Several online databases were searched for articles published until May 13, 2020. Two investigators independently selected trials, extracted data, and evaluated the quality of individual trials. Single-arm meta-analysis was performed to summarize the clinical features of confirmed COVID-19 patients. Fixed effects meta-analysis was performed for clinically relevant parameters that were closely related to the patients’ various organ functions. A total of 73 studies, including 171,108 patients, were included in this analysis. The overall incidence of severe COVID-19 and mortality were 24% (95% confidence interval [CI], 20%-28%) and 2% (95% CI, 1%-3%), respectively. Patients with hypertension (odds ratio [OR] = 2.40; 95% CI, 2.08-2.78), cardiovascular disease (CVD) (OR = 3.54; 95% CI, 2.68-4.68), chronic obstructive pulmonary disease (COPD) (OR=3.70; 95% CI, 2.93-4.68), chronic liver disease (CLD) (OR=1.48; 95% CI, 1.09-2.01), chronic kidney disease (CKD) (OR = 1.84; 95% CI, 1.47-2.30), chronic cerebrovascular diseases (OR = 2.53; 95% CI, 1.84-3.49) and chronic gastrointestinal (GI) disease (OR = 2.13; 95% CI, 1.12-4.05) were more likely to develop severe COVID-19. Increased levels of lactate dehydrogenase (LDH), creatine kinase (CK), high-sensitivity cardiac troponin I (hs-cTnI), myoglobin, creatinine, urea, alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin were highly associated with severe COVID-19. The incidence of acute organ injuries, including acute cardiac injury (ACI); (OR = 11.87; 95% CI, 7.64-18.46), acute kidney injury (AKI); (OR=10.25; 95% CI, 7.60-13.84), acute respiratory distress syndrome (ARDS); (OR=27.66; 95% CI, 18.58-41.18), and acute cerebrovascular diseases (OR=9.22; 95% CI, 1.61-52.72) was more common in patients with severe COVID-19 than in patients with non-severe COVID-19. Patients with a history of organ dysfunction are more susceptible to severe conditions. COVID-19 can aggravate an acute multiorgan injury.

Keywords COVID-19      multiorgan dysfunction      acute multiorgan injury     
Corresponding Authors: Deng Meichun   
About author:

These authors contributed equally to this work.

Just Accepted Date: 30 May 2020   Issue Date: 30 July 2020
E-mail this article
E-mail Alert
Articles by authors
Wu Ting
Zuo Zhihong
Kang Shuntong
Jiang Liping
Luo Xuan
Xia Zanxian
Liu Jing
Xiao Xiaojuan
Ye Mao
Deng Meichun
Cite this article:   
Wu Ting,Zuo Zhihong,Kang Shuntong, et al. Multi-organ Dysfunction in Patients with COVID-19: A Systematic Review and Meta-analysis[J]. Aging and disease, 2020, 11(4): 874-894.
URL:     OR
CFR, % (95%CI)2(1-3)Laboratory results (95%CI)
CSR, % (95%CI)24(20-28)Liver function
Comorbidity, % (95%CI)ALT, U/L27.02(24.67-29.37)
Hypertension19(15-23)AST, U/L30.50(28.09-32.91)
Diabetes10(8-13)Total bilirubin, mmol/L11.10(10.16-12.04)
CVD8(4-14)Renal function
COPD2(2-3)Creatinine, μmol/L69.18(65.22-73.13)
Cerebrovascular diseases3(2-5)Urea mmol/L4.76(4.31-5.22)
CLD3(2-4)Cardiac function
CKD3(1-4)Myoglobin, ng/mL49.96(37.11-62.81)
Tumor3(1-5)CK, U/L84.69(74.51-94.86)
GI disease7(5-8)LDH, U/L275.43(247.82-303.04)
Nervous system disease1(0-2)hs-cTnI, pg/mL13.08(8.22-17.94)
Neurologic symptoms, % (95%CI)CT % (95%CI)
Headache15(9-23)Bilateral involvement of chest radiographs85(78-90)
Dizziness10(7-13)Complications% (95%CI)
Impaired consciousness9(8-10)ARDS12(7-18)
Olfactory and/or taste disorders.54(37-70)ACI6(3-9)
Olfactory disorders28(9-52)Shock6(2-11)
Taste disorders30(12-52)AKI4(1-7)
GI symptoms, % (95%CI)Acute cerebrovascular disease2(1-3)
Anorexia21(14-29)GI symptoms, % (95%CI)
Abdominal pain5(2-10)Nausea7(4-11)
Table 1  Clinical features of COVID-19 cases.
Figure 1.  PRISMA Diagram of Study Selection.
Figure 2.  Relationship between cardiac dysfunction (Hypertension, CVD, CK and LDH) and COVID-19 severity.
Figure 3.  Relationship between cardiac dysfunction (hs-cTnI, myoglobin, ACI and arrhythmia) and COVID-19 severity.
Figure 4.  Relationship between renal dysfunction and COVID-19 severity.
Figure 5.  Relationship between pulmonary dysfunction and COVID-19 severity
Figure 6.  Relationship between liver dysfunction and COVID-19 severity
Figure 7.  Relationship between neurologic dysfunction and COVID-19 severity.
Cardiac function
HypertensionOR = 2.40; 95% CI, 2.08-2.78OR138 = 2.6; 95% CI, 2.2-3.5
CVDOR = 3.54; 95% CI, 2.68-4.68OR = 7.42; 95% CI, 4.34-12.69OR138 = 3.5; 95% CI, 3.1-4.8
LDH U/LWMD = 140.27; 95% CI, 102.18-178.36WMD = 214.14; 95% CI, 31.09-217.19
CK, U/LWMD = 34.01; 95% CI, 9.46 -58.59WMD = 149.91; 95% CI, 94.03-205.79
Renal function
CKDOR = 1.84; 95% CI, 1.47-2.30OR = 7.82; 95% CI, 3.52-17.38OR138= 2.2; 95% CI, 1.7-4.9
Creatinine, μmol/LWMD = 10.40; 95% CI, 8.07 - 12.72WMD = 10.31; 95% CI, 6.76 - 13.85WMD = 109.92; 95% CI, 21.33 to 198.5
Urea mmol/LWMD = 1.61; 95% CI, 1.26 -1.96WMD = 2.52; 95% CI, 1.26 - 3.78WMD = 7.63; 95% CI, 6.52-8.74
Pulmonary function
SmokerOR=1.61; 95% CI, 1.28-2.02OR=13.04; 95% CI, 2.77-61.46
COPDOR = 3.70; 95% CI, 2.93-4.68OR=9.2; 95% CI, 1.2-70.56OR138 = 3.1; 95% CI, 2.6-4.2
Bilateral involvement of chest radiographsOR=4.65; 95% CI, 2.97-7.34OR=5.85 95% CI, 3.74-9.15OR138 =4.89; 95% CI,1.16-20.47
Liver function
CLDOR = 1.48; 95% CI, 1.09-2.01OR=25.35; 95% CI, 7.37-87.19OR=2.36; 95% CI, 1.09-5.10
ALT, U/LWMD = 7.11; 95% CI, 5.47-8.75WMD = 10.08; 95% CI, 0.89-19.27WMD = -3.07; 95% CI, -11.26-5.11
AST, U/LWMD = 16.10; 95% CI, 14.00-18.20WMD = 23.80; 95% CI, 11.32-36.29WMD = 34.81; 95% CI, -4.39-74.02
Total bilirubin, mmol/LWMD = 2.75; 95% CI, 2.11- 3.40WMD = 6.31; 95% CI, 2.07 - 10.55WMD = 7.09; 95% CI, 2.09-12.09
Table 2  Comparison of impacts of organ function on severity of COVID-19, MERS and SARS.
Figure 8.  Relationship between gastrointestinal dysfunction and COVID-19 severity.
[1] de Wilde AH, Snijder EJ, Kikkert M, van Hemert MJ (2018). Host Factors in Coronavirus Replication. Curr Top Microbiol Immunol, 419:1-42.
[2] Hui DS (2017). Epidemic and Emerging Coronaviruses (Severe Acute Respiratory Syndrome and Middle East Respiratory Syndrome). Clin Chest Med, 38:71-86.
[3] Song Z, Xu Y, Bao L, Zhang L, Yu P, Qu Y, et al. (2019). From SARS to MERS, Thrusting Coronaviruses into the Spotlight. Viruses, 11.
[4] Chan KS, Zheng JP, Mok YW, Li YM, Liu YN, Chu CM, et al. (2003). SARS: prognosis, outcome and sequelae. Respirology, 8 Suppl:S36-40.
[5] Badawi A, Ryoo SG (2016). Prevalence of Diabetes in the 2009 Influenza A (H1N1) and the Middle East Respiratory Syndrome Coronavirus: A Systematic Review and Meta-Analysis. J Public Health Res, 5:733.
[6] Schwartz DA, Graham AL (2020). Potential Maternal and Infant Outcomes from (Wuhan) Coronavirus 2019-nCoV Infecting Pregnant Women: Lessons from SARS, MERS, and Other Human Coronavirus Infections. Viruses, 12.
[7] Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. (2020). Prevalence of comorbidities in the novel Wuhan coronavirus (COVID-19) infection: a systematic review and meta-analysis. Int J Infect Dis, 94:91-95.
[8] Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet, 395:497-506.
[9] Qu R, Ling Y, Zhang YH, Wei LY, Chen X, Li X, et al. (2020). Platelet-to-lymphocyte ratio is associated with prognosis in patients with Corona Virus Disease-19. J Med Virol, in press.
[10] Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. (2020). Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet, 398:1054-1062.
[11] Liu KC, Xu P, Lv WF, Qiu XH, Yao JL, Gu JF, et al. (2020). CT manifestations of coronavirus disease-2019: A retrospective analysis of 73 cases by disease severity. Eur J Radiol, 126:108941.
[12] Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. (2020). Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. Jama, in press.
[13] Wan X, Wang W, Liu J, Tong T (2014). Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol, 14:135.
[14] Qu R, Ling Y, Zhang YH, Wei LY, Chen X, Li XM, et al. (2020). Platelet-to-lymphocyte ratio is associated with prognosis in patients with coronavirus disease-19. J Med Virol, in press.
[15] Zhao W, Zhong Z, Xie X, Yu Q, Liu J (2020). Relation Between Chest CT Findings and Clinical Conditions of Coronavirus Disease (COVID-19) Pneumonia: A Multicenter Study. AJR Am J Roentgenol:1-6.
[16] Xu YH, Dong JH, An WM, Lv XY, Yin XP, Zhang JZ, et al. (2020). Clinical and computed tomographic imaging features of novel coronavirus pneumonia caused by SARS-CoV-2. J Infect, 80:394-400.
[17] Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. (2020). Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med, in press.
[18] Li K, Wu J, Wu F, Guo D, Chen L, Fang Z, et al. (2020). The Clinical and Chest CT Features Associated with Severe and Critical COVID-19 Pneumonia. Invest Radiol, 55:327-331.
[19] Qian GQ, Yang NB, Ding F, Ma AHY, Wang ZY, Shen YF, et al. (2020). Epidemiologic and Clinical Characteristics of 91 Hospitalized Patients with COVID-19 in Zhejiang, China: A retrospective, multi-centre case series. Qjm, in press.
[20] Zhang G, Hu C, Luo L, Fang F, Chen Y, Li J, et al. (2020). Clinical features and outcomes of 221 patients with COVID-19 in Wuhan, China. medRxiv:2020.2003.2002.20030452.
[21] Gao Y, Li T, Han M, Li X, Wu D, Xu Y, et al. (2020). Diagnostic Utility of Clinical Laboratory Data Determinations for Patients with the Severe COVID-19. J Med Virol, in press.
[22] Tabata S, Imai K, Kawano S, Ikeda M, Kodama T, Miyoshi K, et al. (2020). Non-severe vs severe symptomatic COVID-19: 104 cases from the outbreak on the cruise ship “Diamond Princess” in Japan. medRxiv:2020.2003.2018.20038125.
[23] Cao M, Zhang D, Wang Y, Lu Y, Zhu X, Li Y, et al. (2020). Clinical Features of Patients Infected with the 2019 Novel Coronavirus (COVID-19) in Shanghai, China. medRxiv:2020.2003.2004.20030395.
[24] Zhang JJ, Dong X, Cao YY, Yuan YD, Yang YB, Yan YQ, et al. (2020). Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy, in press.
[25] Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. (2020). Dysregulation of immune response in patients with COVID-19 in Wuhan, China. Clin Infect Dis, in press.
[26] Mo P, Xing Y, Xiao Y, Deng L, Zhao Q, Wang H, et al. (2020). Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China. Clin Infect Dis, in press.
[27] Liu J, Li S, Liu J, Liang B, Wang X, Wang H, et al. (2020). Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. medRxiv:2020.2002.2016.20023671.
[28] Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, et al. (2020). Clinical and immunologic features in severe and moderate forms of Coronavirus Disease 2019. medRxiv:2020.2002.2016.20023903.
[29] Cai Q, Huang D, Ou P, Yu H, Zhu Z, Xia Z, et al. (2020). COVID-19 in a Designated Infectious Diseases HospitalOutside Hubei Province, China. medRxiv:2020.2002.2017.20024018.
[30] Zheng Y, Huang Z, Ying G, Zhang X, Ye W, Hu Z, et al. (2020). Study of the lymphocyte change between COVID-19 and non-COVID-19 pneumonia cases suggesting other factors besides uncontrolled inflammation contributed to multi-organ injury. medRxiv:2020.2002.2019.20024885.
[31] Lu H, Ai J, Shen Y, Li Y, Li T, Zhou X, et al. (2020). A descriptive study of the impact of diseases control and prevention on the epidemics dynamics and clinical features of SARS-CoV-2 outbreak in Shanghai, lessons learned for metropolis epidemics prevention. medRxiv:2020.2002.2019.20025031.
[32] Lei L, Jian-ya G (2020). Clinical characteristics of 51 patients discharged from hospital with COVID-19 in Chongqing,China. medRxiv:2020.2002.2020.20025536.
[33] Chen X, Zheng F, Qing Y, Ding S, Yang D, Lei C, et al. (2020). Epidemiological and clinical features of 291 cases with coronavirus disease 2019 in areas adjacent to Hubei, China: a double-center observational study. medRxiv:2020.2003.2003.20030353.
[34] Yang W, Cao Q, Qin L, Wang X, Cheng Z, Pan A, et al. (2020). Clinical characteristics and imaging manifestations of the 2019 novel coronavirus disease (COVID-19):A multi-center study in Wenzhou city, Zhejiang, China. J Infect, 80:388-393.
[35] Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. (2020). Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet, 395:507-513.
[36] Xu XW, Wu XX, Jiang XG, Xu KJ, Ying LJ, Ma CL, et al. (2020). Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. Bmj, 368:m606.
[37] Shi H, Han X, Jiang N, Cao Y, Alwalid O, Gu J, et al. (2020). Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect Dis, 20:425-434.
[38] Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. (2020). Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet, 395:1054-1062.
[39] Liu K, Fang YY, Deng Y, Liu W, Wang MF, Ma JP, et al. (2020). Clinical characteristics of novel coronavirus cases in tertiary hospitals in Hubei Province. Chin Med J (Engl), in press.
[40] Wu J, Liu J, Zhao X, Liu C, Wang W, Wang D, et al. (2020). Clinical Characteristics of Imported Cases of COVID-19 in Jiangsu Province: A Multicenter Descriptive Study. Clin Infect Dis, in press.
[41] Liu W, Tao ZW, Lei W, Ming-Li Y, Kui L, Ling Z, et al. (2020). Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. Chin Med J (Engl), in press.
[42] Guan W-j, Liang W-h, Zhao Y, Liang H-r, Chen Z-s, Li Y-m, et al. (2020). Comorbidity and its impact on 1,590 patients with COVID-19 in China: A Nationwide Analysis. medRxiv:2020.2002.2025.20027664.
[43] Yang Y, Lu Q, Liu M, Wang Y, Zhang A, Jalali N, et al. (2020). Epidemiological and clinical features of the 2019 novel coronavirus outbreak in China. medRxiv:2020.2002.2010.20021675.
[44] Zhang Y and The Novel Coronavirus Pneumonia Emergency Response Epidemiology Team. (2020). [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) in China]. Zhonghua Liu Xing Bing Xue Za Zhi, 41:145-151.
[45] Wan S, Xiang Y, Fang W, Zheng Y, Li B, Hu Y, et al. (2020). Clinical features and treatment of COVID-19 patients in northeast Chongqing. J Med Virol, in press.
[46] Xu X, Yu C, Qu J, Zhang L, Jiang S, Huang D, et al. (2020). Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2. Eur J Nucl Med Mol Imaging, 47:1275-1280.
[47] Qi D, Yan X, Tang X, Peng J, Yu Q, Feng L, et al. (2020). Epidemiological and clinical features of 2019-nCoV acute respiratory disease cases in Chongqing municipality, China: a retrospective, descriptive, multiple-center study. medRxiv:2020.2003.2001.20029397.
[48] Zhao W, Yu S, Zha X, Wang N, Pang Q, Li T, et al. (2020). Clinical characteristics and durations of hospitalized patients with COVID-19 in Beijing: a retrospective cohort study. medRxiv: 2020.2003.2013.20035436.
[49] Ma K-L, Liu Z-H, Cao C-f, Liu M-K, Liao J, Zou J-B, et al. (2020). COVID-19 Myocarditis and Severity Factors: An Adult Cohort Study. medRxiv:2020.2003.2019.20034124.
[50] Nie S, Zhao X, Zhao K, Zhang Z, Zhang Z, Zhang Z (2020). Metabolic disturbances and inflammatory dysfunction predict severity of coronavirus disease 2019 (COVID-19): a retrospective study. medRxiv:2020.2003.2024.20042283.
[51] Hu L, Chen S, Fu Y, Gao Z, Long H, Wang JM, et al. (2020). Risk Factors Associated with Clinical Outcomes in 323 COVID-19 Hospitalized Patients in Wuhan, China. Clin Infect Dis, in press.
[52] Petrilli CM, Jones SA, Yang J, Rajagopalan H, O'Donnell LF, Chernyak Y, et al. (2020). Factors associated with hospitalization and critical illness among 4,103 patients with COVID-19 disease in New York City. medRxiv:2020.2004.2008.20057794.
[53] Levinson R, Elbaz M, Ben-Ami R, Shasha D, Levinson T, Choshen G, et al. (2020). Anosmia and dysgeusia in patients with mild SARS-CoV-2 infection. medRxiv:2020.2004.2011.20055483.
[54] Huang Y, Lyu X, Li D, Wang Y, Wang L, Zou W, et al. (2020). A cohort study of 223 patients explores the clinical risk factors for the severity diagnosis of COVID-19. medRxiv:2020.2004.2018.20070656.
[55] Fontanet A, Tondeur L, Madec Y, Grant R, Besombes C, Jolly N, et al. (2020). Cluster of COVID-19 in northern France: A retrospective closed cohort study. medRxiv:2020.2004.2018.20071134.
[56] Paranjpe I, Russak A, De Freitas JK, Lala A, Miotto R, Vaid A, et al. (2020). Clinical Characteristics of Hospitalized Covid-19 Patients in New York City. medRxiv:2020.2004.2019.20062117.
[57] Buscarini E, Manfredi G, Brambilla G, Menozzi F, Londoni C, Alicante S, et al. (2020). Gastrointestinal symptoms as Covid-19 onset in hospitalized Italian patients. medRxiv:2020.2004.2020.20064873.
[58] Docherty AB, Harrison EM, Green CA, Hardwick HE, Pius R, Norman L, et al. (2020). Features of 16,749 hospitalised UK patients with COVID-19 using the ISARIC WHO Clinical Characterisation Protocol. medRxiv:2020.2004.2023.20076042.
[59] Borobia AM, Carcas AJ, Arnalich F, Alvarez-Sala R, Montserrat J, Quintana M, et al. (2020). A cohort of patients with COVID-19 in a major teaching hospital in Europe. medRxiv:2020.2004.2029.20080853.
[60] Cabaraux P, Lechien JR, saussez s, Chiesa-Estomba CM, Khalife M, Hans S, et al. (2020). Objective Olfactory Evaluation of Self-reported Olfactory Dysfunction in a Case Series of 86 COVID-19 Patients. medRxiv:2020.2005.2003.20088526.
[61] Zhang J, Ding D, Cao C, Zhang J, Huang X, Fu P, et al. (2020). Myocardial characteristics as the prognosis for COVID-19 patients. medRxiv:2020.2005.2006.20068882.
[62] Ji W, Huh K, Kang M, Hong J, Bae GH, Lee R, et al. (2020). Effect of underlying comorbidities on the infection and severity of COVID-19 in South Korea. medRxiv:2020.2005.2008.20095174.
[63] Zheng F, Tang W, Li H, Huang YX, Xie YL, Zhou ZG (2020). Clinical characteristics of 161 cases of corona virus disease 2019 (COVID-19) in Changsha. Eur Rev Med Pharmacol Sci, 24:3404-3410.
[64] Wang Z, Yang B, Li Q, Wen L, Zhang R (2020). Clinical Features of 69 Cases with Coronavirus Disease 2019 in Wuhan, China. Clin Infect Dis, in press.
[65] Giacomelli A, Pezzati L, Conti F, Bernacchia D, Siano M, Oreni L, et al. (2020). Self-reported olfactory and taste disorders in SARS-CoV-2 patients: a cross-sectional study. Clin Infect Dis, in press.
[66] Luers JC, Rokohl AC, Loreck N, Wawer Matos PA, Augustin M, Dewald F, et al. (2020). Olfactory and Gustatory Dysfunction in Coronavirus Disease 19 (COVID-19). Clin Infect Dis, in press.
[67] Beltran-Corbellini A, Chico-Garcia JL, Martinez-Poles J, Rodriguez-Jorge F, Natera-Villalba E, Gomez-Corral J, et al. (2020). Acute-onset smell and taste disorders in the context of COVID-19: a pilot multicentre polymerase chain reaction based case-control study. Eur J Neurol, in press.
[68] Lu L, Xiong W, Liu D, Liu J, Yang D, Li N, et al. (2020). New onset acute symptomatic seizure and risk factors in coronavirus disease 2019: A retrospective multicenter study. Epilepsia, in press.
[69] Colaneri M, Sacchi P, Zuccaro V, Biscarini S, Sachs M, Roda S, et al. (2020). Clinical characteristics of coronavirus disease (COVID-19) early findings from a teaching hospital in Pavia, North Italy, 21 to 28 February 2020. Euro Surveill, 25.
[70] Vaira LA, Deiana G, Fois AG, Pirina P, Madeddu G, De Vito A, et al. (2020). Objective evaluation of anosmia and ageusia in COVID-19 patients: Single-center experience on 72 cases. Head Neck, in press.
[71] Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, et al. (2020). Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. JAMA Neurol, in press.
[72] Sun L, Shen L, Fan J, Gu F, Hu M, An Y, et al. (2020). Clinical Features of Patients with Coronavirus Disease 2019 (COVID-19) from a Designated Hospital in Beijing, China. J Med Virol, in press.
[73] Lechien JR, Chiesa-Estomba CM, Place S, Van Laethem Y, Cabaraux P, Mat Q, et al. (2020). Clinical and Epidemiological Characteristics of 1,420 European Patients with mild-to-moderate Coronavirus Disease 2019. J Intern Med, in press.
[74] Zhang Y, Zheng L, Liu L, Zhao M, Xiao J, Zhao Q (2020). Liver impairment in COVID-19 patients: A retrospective analysis of 115 cases from a single centre in Wuhan city, China. Liver Int, in press.
[75] Zheng Y, Xu H, Yang M, Zeng Y, Chen H, Liu R, et al. (2020). Epidemiological characteristics and clinical features of 32 critical and 67 noncritical cases of COVID-19 in Chengdu. J Clin Virol, 127:104366.
[76] Wang R, Pan M, Zhang X, Han M, Fan X, Zhao F, et al. (2020). Epidemiological and clinical features of 125 Hospitalized Patients with COVID-19 in Fuyang, Anhui, China. Int J Infect Dis, 95:421-428.
[77] Zhang J, Yu M, Tong S, Liu LY, Tang LV (2020). Predictive factors for disease progression in hospitalized patients with coronavirus disease 2019 in Wuhan, China. J Clin Virol, 127:104392.
[78] Redd WD, Zhou JC, Hathorn KE, McCarty TR, Bazarbashi AN, Thompson CC, et al. (2020). Prevalence and Characteristics of Gastrointestinal Symptoms in Patients with SARS-CoV-2 Infection in the United States: A Multicenter Cohort Study. Gastroenterology, in press.
[79] Tomlins J, Hamilton F, Gunning S, Sheehy C, Moran E, MacGowan A (2020). Clinical features of 95 sequential hospitalised patients with novel coronavirus 2019 disease (COVID-19), the first UK cohort. J Infect, in press.
[80] Huang R, Zhu L, Xue L, Liu L, Yan X, Wang J, et al. (2020). Clinical findings of patients with coronavirus disease 2019 in Jiangsu province, China: A retrospective, multi-center study. PLoS Negl Trop Dis, 14:e0008280.
[81] Feng Y, Ling Y, Bai T, Xie Y, Huang J, Li J, et al. (2020). COVID-19 with Different Severity: A Multi-center Study of Clinical Features. Am J Respir Crit Care Med, in press.
[82] Menni C, Valdes AM, Freidin MB, Sudre CH, Nguyen LH, Drew DA, et al. (2020). Real-time tracking of self-reported symptoms to predict potential COVID-19. Nat Med, in press.
[83] Liu F, Zhang Q, Huang C, Shi C, Wang L, Shi N, et al. (2020). CT quantification of pneumonia lesions in early days predicts progression to severe illness in a cohort of COVID-19 patients. Theranostics, 10:5613-5622.
[84] Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. (2020). Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res, 30:269-271.
[85] Al-Bari MA (2015). Chloroquine analogues in drug discovery: new directions of uses, mechanisms of actions and toxic manifestations from malaria to multifarious diseases. J Antimicrob Chemother, 70:1608-1621.
[86] Chen Z, Hu J, Zhang Z, Jiang S, Han S, Yan D, et al. (2020). Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial. medRxiv:2020.2003.2022.20040758.
[87] Mahevas M, Tran V-T, Roumier M, Chabrol A, Paule R, Guillaud C, et al. (2020). No evidence of clinical efficacy of hydroxychloroquine in patients hospitalized for COVID-19 infection with oxygen requirement: results of a study using routinely collected data to emulate a target trial. medRxiv:2020.2004.2010.20060699.
[88] Radke JB, Kingery JM, Maakestad J, Krasowski MD (2019). Diagnostic pitfalls and laboratory test interference after hydroxychloroquine intoxication: A case report. Toxicol Rep, 6:1040-1046.
[89] Chorin E, Wadhwani L, Magnani S, Dai M, Shulman E, Nadeau-Routhier C, et al. (2020). QT Interval Prolongation and Torsade De Pointes in Patients with COVID-19 treated with Hydroxychloroquine/Azithromycin. Heart Rhythm, in press.
[90] Touret F, de Lamballerie X (2020). Of chloroquine and COVID-19. Antiviral Res, 177:104762.
[91] Cheng Y, Luo R, Wang K, Zhang M, Wang Z, Dong L, et al. (2020). Kidney disease is associated with in-hospital death of patients with COVID-19. Kidney Int, 97:829-838.
[92] Zhang J, Tian J, Sun H, Digvijay K, Neri M, Bhargava V, et al. (2018). How Does Continuous Renal Replacement Therapy Affect Septic Acute Kidney Injury? Blood Purif, 46:326-331.
[93] Wang L, Li X, Chen H, Yan S, Li D, Li Y, et al. (2020). Coronavirus Disease 19 Infection Does Not Result in Acute Kidney Injury: An Analysis of 116 Hospitalized Patients from Wuhan, China. Am J Nephrol, 51:343-348.
[94] Bellomo R, Cass A, Cole L, Finfer S, Gallagher M, Lo S, et al. (2009). Intensity of continuous renal-replacement therapy in critically ill patients. N Engl J Med, 361:1627-1638.
[95] Zha L, Li S, Pan L, Tefsen B, Li Y, French N, et al. (2020). Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19). Med J Aust, 212:416-420.
[96] Fang X, Mei Q, Yang T, Li L, Wang Y, Tong F, et al. (2020). Low-dose corticosteroid therapy does not delay viral clearance in patients with COVID-19. J Infect, in press.
[97] Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S, et al. (2020). Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med, in press.
[98] Poston JT, Patel BK, Davis AM (2020). Management of Critically Ill Adults With COVID-19. Jama, in press.
[99] Chu CM, Cheng VC, Hung IF, Wong MM, Chan KH, Chan KS, et al. (2004). Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax, 59:252-256.
[100] de Wilde AH, Jochmans D, Posthuma CC, Zevenhoven-Dobbe JC, van Nieuwkoop S, Bestebroer TM, et al. (2014). Screening of an FDA-approved compound library identifies four small-molecule inhibitors of Middle East respiratory syndrome coronavirus replication in cell culture. Antimicrob Agents Chemother, 58:4875-4884.
[101] Chan JF, Yao Y, Yeung ML, Deng W, Bao L, Jia L, et al. (2015). Treatment With Lopinavir/Ritonavir or Interferon-beta1b Improves Outcome of MERS-CoV Infection in a Nonhuman Primate Model of Common Marmoset. J Infect Dis, 212:1904-1913.
[102] Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G, et al. (2020). A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med, 382:1787-1799.
[103] Tian S, Xiong Y, Liu H, Niu L, Guo J, Liao M, et al.2020. Pathological Study of the 2019 Novel Coronavirus Disease (COVID-19) through Post-Mortem Core Biopsies. Mod Pathol, in press.
[104] Fan Z, Chen L, Li J, Cheng X, Yang J, Tian C, et al. (2020). Clinical Features of COVID-19-Related Liver Damage. Clin Gastroenterol Hepatol, in press.
[105] Beyrouti R, Adams ME, Benjamin L, Cohen H, Farmer SF, Goh YY, et al. (2020). Characteristics of ischaemic stroke associated with COVID-19. J Neurol Neurosurg Psychiatry, in press.
[106] Wang M, Zhou Y, Chang J, Xian Y, Mao L, Hong C, et al. (2020). Acute Cerebrovascular Disease Following COVID-19: A Single Center, Retrospective, Observational Study. SSRN Electronic Journal, in press.
[107] Zhang Y, Xiao M, Zhang S, Xia P, Cao W, Jiang W, et al. (2020). Coagulopathy and Antiphospholipid Antibodies in Patients with Covid-19. N Engl J Med, 382:e38.
[108] He Q, Wu C, Luo H, Wang ZY, Ma XQ, Zhao YF, et al. (2014). Trends in in-hospital mortality among patients with stroke in China. PLoS One, 9:e92763.
[109] Qureshi AI, Abd-Allah F, Alsenani F, Aytac E, Borhani-Haghighi A, Ciccone A, et al. (2020). Management of acute ischemic stroke in patients with COVID-19 infection: Report of an international panel. Int J Stroke:1747493020923234.
[110] Tiainen M, Meretoja A, Strbian D, Suvanto J, Curtze S, Lindsberg PJ, et al. (2013). Body temperature, blood infection parameters, and outcome of thrombolysis-treated ischemic stroke patients. Int J Stroke, 8:632-638.
[111] Mao R, Liang J, Shen J, Ghosh S, Zhu LR, Yang H, et al. (2020). Implications of COVID-19 for patients with pre-existing digestive diseases. Lancet Gastroenterol Hepatol, 5:425-427.
[112] Norsa L, Indriolo A, Sansotta N, Cosimo P, Greco S, D'Antiga L (2020). Uneventful course in IBD patients during SARS-CoV-2 outbreak in northern Italy. Gastroenterology, in press.
[113] Mazza S, Sorce A, Peyvandi F, Vecchi M, Caprioli F (2020). A fatal case of COVID-19 pneumonia occurring in a patient with severe acute ulcerative colitis. Gut, 69:1148-1149.
[114] Wisniewski A, Kirchgesner J, Seksik P, Landman C, Bourrier A, Nion-Larmurier I, et al. (2020). Increased incidence of systemic serious viral infections in patients with inflammatory bowel disease associates with active disease and use of thiopurines. United European Gastroenterology Journal, 8:303-313.
[115] Ford AC, Peyrin-Biroulet L (2013). Opportunistic infections with anti-tumor necrosis factor-alpha therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials. Am J Gastroenterol, 108:1268-1276.
[116] Taxonera C, Sagastagoitia I, Alba C, Manas N, Olivares D, Rey E (2020). 2019 Novel Coronavirus Disease (COVID-19) in patients with Inflammatory Bowel Diseases. Aliment Pharmacol Ther, in press.
[117] Monteleone G, Ardizzone S (2020). Are patients with inflammatory bowel disease at increased risk for Covid-19 infection? J Crohns Colitis, in press.
[118] D'Amico F, Peyrin-Biroulet L, Danese S (2020). Inflammatory Bowel Diseases and COVID-19: The Invisible Enemy. Gastroenterology, in press.
[119] Zou Z, Yang Y, Chen J, Xin S, Zhang W, Zhou X, et al. (2004). Prognostic factors for severe acute respiratory syndrome: a clinical analysis of 165 cases. Clin Infect Dis, 38:483-489.
[120] Choi KW, Chau TN, Tsang O, Tso E, Chiu MC, Tong WL, et al. (2003). Outcomes and prognostic factors in 267 patients with severe acute respiratory syndrome in Hong Kong. Ann Intern Med, 139:715-723.
[121] Hui DS, Wong KT, Antonio GE, Ahuja A, Sung JJ (2009). Correlation of clinical outcomes and radiographic features in SARS patients. Hong Kong Med J, 15 Suppl 8:24-28.
[122] Lew TW, Kwek TK, Tai D, Earnest A, Loo S, Singh K, et al. (2003). Acute respiratory distress syndrome in critically ill patients with severe acute respiratory syndrome. Jama, 290:374-380.
[123] Chan JC, Tsui EL, Wong VC (2007). Prognostication in severe acute respiratory syndrome: a retrospective time-course analysis of 1312 laboratory-confirmed patients in Hong Kong. Respirology, 12:531-542.
[124] Jang TN, Yeh DY, Shen SH, Huang CH, Jiang JS, Kao SJ (2004). Severe acute respiratory syndrome in Taiwan: analysis of epidemiological characteristics in 29 cases. J Infect, 48:23-31.
[125] Booth CM, Matukas LM, Tomlinson GA, Rachlis AR, Rose DB, Dwosh HA, et al. (2003). Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. Jama, 289:2801-2809.
[126] Lee N, Hui D, Wu A, Chan P, Cameron P, Joynt GM, et al. (2003). A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med, 348:1986-1994.
[127] Peiris JS, Chu CM, Cheng VC, Chan KS, Hung IF, Poon LL, et al. (2003). Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet, 361:1767-1772.
[128] Yu CM, Wong RS, Wu EB, Kong SL, Wong J, Yip GW, et al. (2006). Cardiovascular complications of severe acute respiratory syndrome. Postgrad Med J, 82:140-144.
[129] Fowler RA, Lapinsky SE, Hallett D, Detsky AS, Sibbald WJ, Slutsky AS, et al. (2003). Critically ill patients with severe acute respiratory syndrome. Jama, 290:367-373.
[130] Alfaraj SH, Al-Tawfiq JA, Assiri AY, Alzahrani NA, Alanazi AA, Memish ZA (2019). Clinical predictors of mortality of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection: A cohort study. Travel Med Infect Dis, 29:48-50.
[131] Arabi YM, Al-Omari A, Mandourah Y, Al-Hameed F, Sindi AA, Alraddadi B, et al. (2017). Critically Ill Patients With the Middle East Respiratory Syndrome: A Multicenter Retrospective Cohort Study. Crit Care Med, 45:1683-1695.
[132] Sherbini N, Iskandrani A, Kharaba A, Khalid G, Abduljawad M, Al-Jahdali H (2017). Middle East respiratory syndrome coronavirus in Al-Madinah City, Saudi Arabia: Demographic, clinical and survival data. J Epidemiol Glob Health, 7:29-36.
[133] Choi WS, Kang CI, Kim Y, Choi JP, Joh JS, Shin HS, et al. (2016). Clinical Presentation and Outcomes of Middle East Respiratory Syndrome in the Republic of Korea. Infect Chemother, 48:118-126.
[134] Assiri A, Abedi GR, Bin Saeed AA, Abdalla MA, al-Masry M, Choudhry AJ, et al. (2016). Multifacility Outbreak of Middle East Respiratory Syndrome in Taif, Saudi Arabia. Emerg Infect Dis, 22:32-40.
[135] Almekhlafi GA, Albarrak MM, Mandourah Y, Hassan S, Alwan A, Abudayah A, et al. (2016). Presentation and outcome of Middle East respiratory syndrome in Saudi intensive care unit patients. Crit Care, 20:123.
[136] Alqahtani FY, Aleanizy FS, Ali El Hadi Mohamed R, Alanazi MS, Mohamed N, Alrasheed MM, et al. (2018). Prevalence of comorbidities in cases of Middle East respiratory syndrome coronavirus: a retrospective study. Epidemiol Infect:1-5.
[137] Chau TN, Lee PO, Choi KW, Lee CM, Ma KF, Tsang TY, et al. (2004). Value of initial chest radiographs for predicting clinical outcomes in patients with severe acute respiratory syndrome. Am J Med, 117:249-254.
[138] Matsuyama R, Nishiura H, Kutsuna S, Hayakawa K, Ohmagari N (2016). Clinical determinants of the severity of Middle East respiratory syndrome (MERS): a systematic review and meta-analysis. BMC Public Health, 16:1203.
[139] Fang L, Gao P, Bao H, Tang X, Wang B, Feng Y, et al. (2018). Chronic obstructive pulmonary disease in China: a nationwide prevalence study. Lancet Respir Med, 6:421-430.
[140] Wang Z, Chen Z, Zhang L, Wang X, Hao G, Zhang Z, et al. (2018). Status of Hypertension in China: Results From the China Hypertension Survey, 2012-2015. Circulation, 137:2344-2356.
[141] Zhao X, Zhang B, Li P, Ma C, Gu J, Hou P, et al. (2020). Incidence, clinical characteristics and prognostic factor of patients with COVID-19: a systematic review and meta-analysis. medRxiv:2020.2003.2017.20037572.
[142] de Wit E, van Doremalen N, Falzarano D, Munster VJ (2016). SARS and MERS: recent insights into emerging coronaviruses. Nat Rev Microbiol, 14:523-534.
[143] Lande R, Gilliet M (2010). Plasmacytoid dendritic cells: key players in the initiation and regulation of immune responses. Ann N Y Acad Sci, 1183:89-103.
[144] Prompetchara E, Ketloy C, Palaga T (2020). Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic. Asian Pac J Allergy Immunol, 38:1-9.
[145] Channappanavar R, Perlman S (2017). Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol, 39:529-539.
[146] Furman D, Campisi J, Verdin E, Carrera-Bastos P, Targ S, Franceschi C, et al. (2019). Chronic inflammation in the etiology of disease across the life span. Nat Med, 25:1822-1832.
[147] Li Z, Wu M, Yao J, Guo J, Liao X, Song S, et al. (2020). Caution on Kidney Dysfunctions of COVID-19 Patients. medRxiv:2020.2002.2008.20021212.
[148] Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, et al. (2020). Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol, in press.
[149] Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. (2020). A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature, 579:270-273.
[150] Crackower MA, Sarao R, Oudit GY, Yagil C, Kozieradzki I, Scanga SE, et al. (2002). Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature, 417:822-828.
[151] Fan C, Li K, Ding Y, Lu WL, Wang J (2020). ACE2 Expression in Kidney and Testis May Cause Kidney and Testis Damage After 2019-nCoV Infection. medRxiv:2020.2002.2012.20022418.
[152] Zhang H, Li HB, Lyu JR, Lei XM, Li W, Wu G, et al. (2020). Specific ACE2 expression in small intestinal enterocytes may cause gastrointestinal symptoms and injury after 2019-nCoV infection. Int J Infect Dis, 96:19-24.
[153] Zhang H, Zhou P, Wei Y, Yue H, Wang Y, Hu M, et al. (2020). Histopathologic Changes and SARS-CoV-2 Immunostaining in the Lung of a Patient With COVID-19. Ann Intern Med, 172:629-632.
[154] Diao B, Wang C, Wang R, Feng Z, Tan Y, Wang H, et al. (2020). Human Kidney is a Target for Novel Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection. medRxiv:2020.2003.2004.20031120.
[155] Su H, Yang M, Wan C, Yi LX, Tang F, Zhu HY, et al. (2020). Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in China. Kidney Int, in press.
[156] Xu Z, Shi L, Wang Y, Zhang J, Huang L, Zhang C, et al. (2020). Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med, 8:420-422.
[157] Yao XH, Li TY, He ZC, Ping YF, Liu HW, Yu SC, et al. (2020). [A pathological report of three COVID-19 cases by minimally invasive autopsies]. Zhonghua Bing Li Xue Za Zhi, 49:E009.
[158] Wichmann D, Sperhake JP, Lütgehetmann M, Steurer S, Edler C, Heinemann A, et al. (2020). Autopsy Findings and Venous Thromboembolism in Patients With COVID-19: A Prospective Cohort Study. Ann Intern Med, in press.
[159] Netland J, Meyerholz DK, Moore S, Cassell M, Perlman S (2008). Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2. J Virol, 82:7264-7275.
[160] Moriguchi T, Harii N, Goto J, Harada D, Sugawara H, Takamino J, et al. (2020). A first case of meningitis/encephalitis associated with SARS-Coronavirus-2. Int J Infect Dis, 94:55-58.
[161] Xiao F, Tang M, Zheng X, Liu Y, Li X, Shan H (2020). Evidence for Gastrointestinal Infection of SARS-CoV-2. Gastroenterology, 158:1831-1833.e1833.
[162] Yong Z, Cao C, Shuangli Z, Chang S, Dongyan W, Jingdong S, et al. (2020). Isolation of 2019-nCoV from a Stool Specimen of a Laboratory-Confirmed Case of the Coronavirus Disease 2019 (COVID-19). China CDC Weekly, 2:123-124.
[163] Lu R, Zhao X, Li J, Niu P, Yang B, Wu H, et al. (2020). Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet, 395:565-574.
[164] Kang S, Peng W, Zhu Y, Lu S, Zhou M, Lin W, et al. (2020). Recent progress in understanding 2019 novel coronavirus (SARS-CoV-2) associated with human respiratory disease: detection, mechanisms and treatment. Int J Antimicrob Agents:105950.
[165] Alagaili AN, Briese T, Mishra N, Kapoor V, Sameroff SC, Burbelo PD, et al. (2014). Middle East respiratory syndrome coronavirus infection in dromedary camels in Saudi Arabia. mBio, 5:e00884-00814.
[166] Wang N, Shi X, Jiang L, Zhang S, Wang D, Tong P, et al. (2013). Structure of MERS-CoV spike receptor-binding domain complexed with human receptor DPP4. Cell Res, 23:986-993.
[167] Ding Y, Wang H, Shen H, Li Z, Geng J, Han H, et al. (2003). The clinical pathology of severe acute respiratory syndrome (SARS): a report from China. J Pathol, 200:282-289.
[168] Ng DL, Al Hosani F, Keating MK, Gerber SI, Jones TL, Metcalfe MG, et al. (2016). Clinicopathologic, Immunohistochemical, and Ultrastructural Findings of a Fatal Case of Middle East Respiratory Syndrome Coronavirus Infection in the United Arab Emirates, April 2014. Am J Pathol, 186:652-658.
[1] Supplementary data Download
[1] Das Undurti N. Bioactive Lipids as Mediators of the Beneficial Action(s) of Mesenchymal Stem Cells in COVID-19[J]. Aging and disease, 2020, 11(4): 746-755.
[2] Lara Pedro C,Macías-Verde David,Burgos-Burgos Javier. Age-induced NLRP3 Inflammasome Over-activation Increases Lethality of SARS-CoV-2 Pneumonia in Elderly Patients[J]. Aging and disease, 2020, 11(4): 756-762.
[3] Barzilai Nir,Appleby James C,Austad Steven N,Cuervo Ana Maria,Kaeberlein Matt,Gonzalez-Billault Christian,Lederman Stephanie,Stambler Ilia,Sierra Felipe. Geroscience in the Age of COVID-19[J]. Aging and disease, 2020, 11(4): 725-729.
[4] He Feng,Quan Yibo,Lei Ming,Liu Riguang,Qin Shuguang,Zeng Jun,Zhao Ziwen,Yu Na,Yang Liuping,Cao Jie. Clinical features and risk factors for ICU admission in COVID-19 patients with cardiovascular diseases[J]. Aging and disease, 2020, 11(4): 763-769.
[5] Schwartz Michael D,Emerson Stephen G,Punt Jennifer,Goff Willow D. Decreased Naïve T-cell Production Leading to Cytokine Storm as Cause of Increased COVID-19 Severity with Comorbidities[J]. Aging and disease, 2020, 11(4): 742-745.
[6] Pietro Gentile, Aris Sterodimas. Adipose Stem Cells (ASCs) and Stromal Vascular Fraction (SVF) as a Potential Therapy in Combating (COVID-19)-Disease[J]. Aging and disease, 2020, 11(3): 465-469.
[7] Hong Liu, Shiyan Chen, Min Liu, Hao Nie, Hongyun Lu. Comorbid Chronic Diseases are Strongly Correlated with Disease Severity among COVID-19 Patients: A Systematic Review and Meta-Analysis[J]. Aging and disease, 2020, 11(3): 668-678.
[8] Selçuk Öztürk, Ayşe Eser Elçin, Yaşar Murat Elçin. Mesenchymal Stem Cells for Coronavirus (COVID-19)-Induced Pneumonia: Revisiting the Paracrine Hypothesis with New Hopes?[J]. Aging and disease, 2020, 11(3): 477-479.
[9] Sankha Shubhra Chakrabarti, Upinder Kaur, Anindita Banerjee, Upasana Ganguly, Tuhina Banerjee, Sarama Saha, Gaurav Parashar, Suvarna Prasad, Suddhachitta Chakrabarti, Amit Mittal, Bimal Kumar Agrawal, Ravindra Kumar Rawal, Robert Chunhua Zhao, Indrajeet Singh Gambhir, Rahul Khanna, Ashok K Shetty, Kunlin Jin, Sasanka Chakrabarti. COVID-19 in India: Are Biological and Environmental Factors Helping to Stem the Incidence and Severity?[J]. Aging and disease, 2020, 11(3): 480-488.
[10] Xiaotian Dong, Mengyan Wang, Shuangchun Liu, Jiaqi Zhu, Yanping Xu, Hongcui Cao, Lanjuan Li. Immune Characteristics of Patients with Coronavirus Disease 2019 (COVID-19)[J]. Aging and disease, 2020, 11(3): 642-648.
[11] Zikuan Leng, Rongjia Zhu, Wei Hou, Yingmei Feng, Yanlei Yang, Qin Han, Guangliang Shan, Fanyan Meng, Dongshu Du, Shihua Wang, Junfen Fan, Wenjing Wang, Luchan Deng, Hongbo Shi, Hongjun Li, Zhongjie Hu, Fengchun Zhang, Jinming Gao, Hongjian Liu, Xiaoxia Li, Yangyang Zhao, Kan Yin, Xijing He, Zhengchao Gao, Yibin Wang, Bo Yang, Ronghua Jin, Ilia Stambler, Lee Wei Lim, Huanxing Su, Alexey Moskalev, Antonio Cano, Sasanka Chakrabarti, Kyung-Jin Min, Georgina Ellison-Hughes, Calogero Caruso, Kunlin Jin, Robert Chunhua Zhao. Transplantation of ACE2- Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia[J]. Aging and disease, 2020, 11(2): 216-228.
Full text



Copyright © 2014 Aging and Disease, All Rights Reserved.
Address: Aging and Disease Editorial Office 3400 Camp Bowie Boulevard Fort Worth, TX76106 USA
Fax: (817) 735-0408 E-mail:
Powered by Beijing Magtech Co. Ltd